STOCK TITAN

Arcus Biosciences (RCUS) director Antoni Ribas receives RSU and option awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Arcus Biosciences director Antoni Ribas reported new equity awards and updated his holdings. He received 5,700 shares of Common Stock as restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders, and they fully vest if the company undergoes a change in control. He was also granted a stock option for 16,900 shares at an exercise price of $23.30 per share, with the option vesting on the same schedule and also accelerating upon a change in control. Following these awards, Ribas directly owns 44,300 Common Stock shares and holds an additional 8,553 shares indirectly through a trust.

Positive

  • None.

Negative

  • None.
Insider Ribas Antoni
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 16,900 $0.00 --
Grant/Award Common Stock 5,700 $0.00 --
holding Common Stock -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 16,900 shares (Direct, null); Common Stock — 44,300 shares (Direct, null); Common Stock — 8,553 shares (Indirect, By Trust)
Footnotes (1)
  1. Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.
RSU grant 5,700 shares Restricted stock units vesting by June 11, 2027 or next annual meeting
Stock option grant 16,900 shares Option award reported as of June 11, 2026
Option exercise price $23.30 per share Exercise price for 16,900-share stock option
Option expiration June 10, 2036 Expiration date of the stock option if unexercised
Direct holdings after transaction 44,300 shares Common Stock directly owned after June 11, 2026 awards
Indirect holdings via trust 8,553 shares Common Stock held indirectly by trust after transaction
restricted stock units financial
"Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
change in control financial
"The RSUs will become fully vested in the event the Company is subject to a change in control."
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
stock option financial
"The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
annual meeting of stockholders financial
"vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer"
exercise price financial
"conversion_or_exercise_price": "23.3000""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ribas Antoni

(Last)(First)(Middle)
C/O ARCUS BIOSCIENCES, INC.
3928 POINT EDEN WAY

(Street)
HAYWARD CALIFORNIA 94545

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Arcus Biosciences, Inc. [ RCUS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/11/2026A5,700(1)A$044,300D
Common Stock8,553IBy Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$23.306/11/2026A16,900 (2)06/10/2036Stock Option (Rights to Buy)16,900$016,900D
Explanation of Responses:
1. Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.
2. The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.
Remarks:
/s/ Carolyn Tang, Attorney-in-Fact06/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Arcus Biosciences (RCUS) director Antoni Ribas acquire in this Form 4?

Antoni Ribas received equity compensation, not an open-market purchase. He was granted 5,700 restricted stock units of Arcus Biosciences Common Stock and a stock option covering 16,900 shares, both as awards with no cash price per share at grant.

How many Arcus Biosciences (RCUS) shares does Antoni Ribas hold after these grants?

After the reported grants, Antoni Ribas holds 44,300 shares of Arcus Biosciences Common Stock directly. He also has an additional 8,553 shares held indirectly through a trust, reflecting both personal and trust-related ownership positions disclosed in this filing.

When do Antoni Ribas’s new RSUs in Arcus Biosciences (RCUS) vest?

The 5,700 restricted stock units vest in full on the earlier of June 11, 2027 or the next annual meeting of Arcus Biosciences stockholders. This means vesting is tied to either a fixed date or the company’s next annual shareholder meeting.

What are the key terms of Antoni Ribas’s new Arcus Biosciences stock option?

The stock option covers 16,900 shares of Arcus Biosciences Common Stock with a $23.30 exercise price per share. It vests in full on the earlier of June 11, 2027 or the next annual meeting of stockholders and expires on June 10, 2036 if not exercised.

How does a change in control affect Antoni Ribas’s new Arcus Biosciences awards?

Both the restricted stock units and the stock option become fully vested if Arcus Biosciences experiences a change in control. This acceleration provision means all 5,700 RSUs and 16,900 option shares would vest immediately upon such a qualifying corporate event.

Are Antoni Ribas’s Arcus Biosciences shares held directly or through a trust?

Antoni Ribas holds Arcus Biosciences shares both ways. The filing shows 44,300 shares held directly in his name and 8,553 shares held indirectly by a trust, reflecting separate ownership categories within his overall disclosed position.